Group items tagged

NHS England will collaborate with "a number of system suppliers" to increase the number of trusts using electronic prescription service (EPS) over the next few years. Nishali Patel, clinical lead for digital medicines at NHS England, announced it during the Clinical Pharmacy Congress, held at the Excel, London, on Friday, 10 May 2024. According to Nishali, at least half of all NHS secondary care trusts could be using EPS by 2026. This digital service allows prescribers to send prescriptions electronically to a patient-nominated pharmacy. It is widely used in primary care, where over 95 per cent of prescriptions are now electronically generated. NHS recently extended the service to secondary care settings.

Grundon Waste Management has introduced what it claims to be the UK's first verified nationwide inhaler return and recycling initiative. NHS Trusts and community pharmacies participating in the new scheme will have specialised recycling containers for inhalers installed to simplify public participation, Grundon said in a statement. Inhalers alone contribute to 4 per cent of NHS CO2 emissions, with around 73 million dispensed annually. By 2026, the health service aims to achieve a 50 per cent reduction in carbon emissions from waste management, a target that rises to 80 percent between 2028 and 2032, as outlined in the NHS Clinical Waste Strategy. "This scheme holds the potential to revolutionise the approach of NHS Trusts towards achieving heightened carbon savings and ultimately, net zero emissions," said Chris Edwards, Grundon's General Manager - Technical. "Each discarded pressurised Metered Dose Inhaler (pMDI) contains highly polluting hydrofluorocarbon (HFC) gases - a category of greenhouse gas known to be over a thousand times more detrimental than carbon dioxide in driving climate change." "This initiative securely captures these gases and repurposes them for application in the refrigeration sector. By also recycling the plastic and aluminium components of the device, we are making a noteworthy contribution to the circular economy," he added. Once collected, these will undergo processing at Grundon's specialist recycling facility in Ewelme, Oxfordshire, which is capable of handling more than 200,000 inhalers a day. The company aims to recycle 80 per cent of all prescribed inhalers by 2025, the statement added.

The government has unveiled its much awaited 'NHS Long-Term Workforce Plan' to tackle the staff shortage in the pharmacy sector. The plan set out an ambition to increase the training places for pharmacists to around 5,000 places by 2031/32. David Webb, Chief Pharmaceutical Officer for England, in his open letter to pharmacy professionals said: "The NHS LTWP sets out how we can build on changes, addressing the changing needs of patients over the next 15 years, by closing the current workforce shortfall through funding for increased education and training places and a comprehensive retention strategy." The plan commits to expand training places for pharmacists by 29% to around 4,300 by 2028/29 and Grow the number of pharmacy technicians in future years. "The development of independent prescribing as part of initial education and training is a gamechanger for pharmacists, patients and the NHS, with approximately 2,800 newly registered pharmacist independent prescribers due to join the workforce every year from September 2026," said Webb. "This will be transformational for all pharmacy teams, creating improved access and quality of care for patients and, importantly, a more flexible workforce with skills that are equally applicable in all pharmacy settings, enabling multi-professional clinical teams to work in new ways."

England's chief pharmaceutical officer (CPhO) David Webb has promised his "wholehearted support" for the community pharmacy sector at the board meeting of the National Pharmacy Association (NPA) on 28 June in St Albans. After hearing the CPhO at the meeting, NPA chair, Andrew Lane, later declared: "David is someone we can do business with." Webb thus listed his priorities as head of profession: integration of independent prescribing as part of pharmacy practice by 2026; promotion of inclusive pharmacy practice for all pharmacy professionals; assurance of post-registration practice; developing the role of pharmacy technicians; support for Integrated Care Systems and Primary Care Network pharmacy teams (including community pharmacy); medicines optimisation; and strengthening of professional leadership for community pharmacy. He also reported that NHS England had recently increased its team of regional pharmacy integration leads from seven to 14, creating seven new senior posts. Webb told NPA board members: "I want sincerely to thank community pharmacy teams for everything they are doing and to say that you have my wholehearted support. I believe in the importance of community pharmacy and will listen and engage as I've already demonstrated.

Boots is planning to invest more than £3.5 million to accelerate its capacity to offer prescribing services in its stores across England. The company is inviting 500 of its pharmacists to apply for a bursary which will cover the cost of pharmacist independent prescriber (PIP) courses starting this September. The value of the bursary is up to £7,000 per pharmacist, and it will enable time off work for those who need it to complete the training. The move by Boots will support its current pharmacists to gain this qualification via courses accredited by the General Pharmaceutical Council (GPhC). From 2026, all qualified pharmacists will be able to prescribe as part of new curricula for pharmacy degrees. Under current GPhC guidelines and with an independent prescribing qualification, pharmacists can prescribe autonomously for any condition within their clinical competence. Marc Donovan, the chief pharmacist at Boots, said the ambition of the company was "to have a pharmacist prescriber available at every store".

The Pharmacists' Defence Association (PDA) has raised concern over the Health Education England (HEE)'s decision on cutting funding to independent prescribing training. The HEE has reportedly decided that no funding will be available to back-fill trainees undertaking the pharmacist independent prescribing (PIP) qualification, or for the supervision of trainees by DPPs and DMPs. The PDA noted that, whilst all successful trainee pharmacists will be entering the GPhC register as independent prescribers from 2026, the existing pharmacist workforce is reliant on opportunities to undertake prescriber training through release from their employment, and the ability to secure a Designated Medical Practitioner (DMP) or Designated Prescribing Practitioner (DPP) to support the 90 days of supervised practice required. The association said it has already heard examples of potential DMPs or DPPs requesting a significant fee from trainees before they will provide supervision, adding that meeting that request is not an option for many. "This latest decision threatens to undermine the availability of the large numbers of pharmacists seeing supervisors as more IP training becomes available," it said in a statement.

British drugmaker GSK has signed deals with three companies allowing them to make inexpensive generic versions of its long-acting HIV preventive medicine for use in lower-income countries, where the majority of new HIV cases occur. The injected drug cabotegravir is approved by regulators in Britain and the United States. Last July, GSK announced a program with the United Nations-backed healthcare organisation, the Medicines Patent Pool, aiming to get poor countries access to new HIV therapies far earlier than they did for previous HIV medicines. During the HIV/AIDs epidemic in Africa in the 1990s and early 2000s, in which many millions of people died, treatments used widely in wealthy countries were unavailable on the continent. GSK said last year the new program could result in the generic form of its injection being available in lower-income countries beginning in 2026. The drugmaker's HIV treatment division, ViiV Healthcare, said in a statement on Wednesday it had issued voluntary licenses - waiving intellectual property rights - to Aurobindo, Cipla and Viatris, which will manufacture the generic versions of injectable cabotegravir.

Community pharmacies will be able to deliver approximately 15 million blood pressure screenings by 2026, revealed the Company Chemists' Association (CCA)'s new research. This will also prevent 15,000 people from suffering heart attacks or strokes. CCA has called the Government to take up their offer and commission pharmacies as the first port of call for cardiovascular care. "Thousands of lives can be saved with ambitious commissioning and the investment to match," said CCA. There is an opportunity to use the expertise of community pharmacy to go further and provide the care these newly identified patients' need. To do this the sector needs funding and workforce. The association said: "Community pharmacy is under great financial pressure, suffering a real term funding cut of over 30% over 8 years. With funding, the sector can transform to deliver this critical need for patients. Whilst there are plans to train Independent Prescribers (IPs), there are no clear roles for them to use these skills. There is a need to accelerate training plans to allow pharmacists to deliver the service described here and play their part in CVD management."

The government has allocated an additional 350 medical school places in England, making a significant step in delivering the NHS Long Term Workforce Plan. Supported by more than £2.4 billion in government funding, the plan outlines the strategy for recruiting and retaining hundreds of thousands more staff over the next 15 years to deliver the future workforce the NHS requires. One of the key commitments of the NHS Long Term Workforce Plan is to double the number of medical school places in England to 15,000 by 2031. As part of the ongoing efforts to fulfill this pledge, the Office for Students (OfS) has designated 350 places for medical schools nationwide for the academic year 2025 to 2026, targeting under-doctored areas.

Northern Ireland's Health Minister, Mike Nesbitt, has welcomed the launch of the 2024/25 Experiential Learning (EL) Programme, designed to equip future pharmacists with the skills needed for a greater role in clinical care. Starting in 2026, pharmacy undergraduate students will qualify as independent prescribers upon registration, and this programme is designed to prepare them for that responsibility. The EL Programme provides pharmacy students with multi-sector clinical work placements across the region. Speaking at the programme's launch at Ulster Hospital, Minister Nesbitt said: "This is the second year of this successful programme, which will see pharmacy students in Northern Ireland benefit from the training by completing up to twelve weeks of practice-based learning in hospitals, community pharmacies and general practices across NI. "This will provide them with actual practice-based experiences in a range of healthcare settings, facilitating them to interact with patients and engage in interprofessional practice.

Chancellor of the Exchequer, Rachel Reeves, presented the Labour government 's Autumn Budget 2024 in the House of Commons on Wednesday, describing it as "a Budget to fix the foundations of the economy and deliver change by protecting working people, fixing the NHS and rebuilding Britain." The Budget, the first from a Labour government in 14 years, introduces some significant measures to boost small businesses and deliver crucial support to the NHS amid challenging economic conditions. In a move to support businesses, the government has announced a fairer business rates system by permanently lowering the business rates multipliers for retail, hospitality, and leisure (RHL) properties from 2026-27. Additionally, £1.9 billion has been allocated to support small businesses and the high street in 2025-26, including freezing the small business multiplier and providing a 40% relief on RHL property bills, up to a £110,000 cash cap. To repair the public finances and raise funding for public services, the government has decided to increase the employer National Insurance Contributions (NICs) rate by 1.2 percentage points to 15%, with effect from 6 April 2025.

NHS England has announced a phased implementation for mandatory multi-sector rotations in the Foundation Pharmacist Training Programme, delaying the full rollout to the 2027/28 training year. Under the General Pharmaceutical Council's Standards for Initial Education and Training of Pharmacists (2021), multi-sector rotations - where trainees spend at least 13 weeks in a different pharmacy setting- were initially planned for all trainees starting in 2026/27. These rotations are designed to enhance pharmacists' adaptability, multi-professional collaboration, and ability to deliver person-centred care across healthcare systems. Acknowledging significant progress from pharmacy employers in developing these programmes, NHS England cited current workforce pressures as a key reason for introducing a phased approach. "We are mindful of the current pressures faced by pharmacy teams and the broader healthcare sector and greatly appreciate your continued commitment to delivering high-quality training. To support pharmacy teams in continuing to deliver high quality training, mandatory rotations will be delayed, and a phased approach will be implemented," David Webb, chief pharmaceutical officer for England and Samantha Illingworth, director of education quality and reform at NHS England, wrote in a letter to training programme providers.

The Department of Health and Social Care (DHSC) has proposed a 2.8% pay uplift for NHS Agenda for Change (AfC) staff, including hospital pharmacists, for the 2025/2026 pay round. This recommendation was detailed in the DHSC's submission to the NHS Pay Review Body (NHSPRB), which described the figure as "a reasonable amount to have set aside based on the macroeconomic data and forecasts and taking into account the fiscal and labour market context." NHS England also supported the 2.8% pay increase, stating that its proposal reflects "the likely NHS budget from discussions to date with DHSC and what was set out by HM Treasury in the Autumn Budget 2024." "We propose to set allocations for NHS planning on the basis of a 2.8% pay settlement. Every 0.5% increase above that costs around £700m; which is the equivalent to around 2% of elective activity (greater than 300k completed patient pathways)," it added. However, Unite the Union, representing NHS staff, condemned the DHSC's recommendation, called the proposed increase "an insult."

Pharmacists are being notified of a limited supply of hydrocortisone sodium phosphate 100mg/1ml solution for injection ampoules, with stock expected to be exhausted by late March 2025. The Department of Health and Social Care (DHSC) has issued a medicine supply notification, indicating that resupply is not anticipated until May 2026. NHS provider Trust pharmacy procurement and clinical teams are advised to collaborate in reserving existing stock of the solution for injection, specifically for patients who require hydrocortisone sodium phosphate during an adrenal crisis. The DHSC added that this stock has an expiry date of June 2025. Hydrocortisone is used to replace steroids in individuals with adrenal insufficiency, such as those with Congenital Adrenal Hyperplasia (CAH) or Addison's disease, where the adrenal glands produce insufficient natural steroids. People with adrenal insufficiency or anyone who is "steroid-dependent" require a hydrocortisone emergency injection kit to prevent an acute adrenal crisis, which can be life-threatening.

Black Haircare Market Report covers key strategic developments of the market including acquisitions & mergers, new type launch, agreements, partnerships, collaborations & joint ventures, research & development, regional expansion of major participants involved in the black haircare market on a global and regional basis. To give the users of this report a comprehensive view on the black haircare market competitive landscape and analysis of Porter's Five Forces model for the market are included in the report. The study encompasses market attractiveness analysis, wherein all segments are benchmarked based on their market size, growth rate and general attractiveness.

Premenstrual Syndrome Treatment Market Research Report By Region, Types and Application